文献速递艾滋病与性传播感染

人类免疫缺陷病毒(HIV)成人患者从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺后的代谢相关结局:多中心前瞻性队列研究

Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study.
PubMed 文献 · Clin Infect Dis · 2023-01-01

西班牙CoRIS多中心前瞻性队列研究,将病毒学抑制的HIV成人按倾向评分匹配,比较转换为替诺福韦艾拉酚胺(TAF)与继续使用富马酸替诺福韦二吡呋酯(TDF)者144周内体重、血脂及代谢相关临床事件的变化。转换至TAF者体重平均增加+0.5 kg,总胆固醇升高+7.9 mg/dL、甘油三酯升高+11.2 mg/dL,但糖尿病、高血压及降脂药物使用发生率未见增加。

要点

  • 转换为TAF者较继续TDF者144周体重平均增加+0.5 kg,超重或肥胖发生率无差异。
  • 转换为TAF者总胆固醇升高+7.9 mg/dL、甘油三酯升高+11.2 mg/dL,总胆固醇-HDL比值无差异。
  • 随访期间糖尿病、高血压及降脂药物使用发生率未见增加。

核心结论

  • 在西班牙以白人男性为主的队列中,从TDF转换为TAF与体重轻度增加及总胆固醇和甘油三酯升高相关,但未影响肥胖或代谢相关临床事件的发生率。

研究设计与样本

  • 西班牙CoRIS队列的多中心前瞻性队列研究,纳入病毒学抑制且接受TDF超过12个月的HIV成人,分为转换为TAF组或继续TDF组,核心药物不变,按倾向评分匹配,每组1446人。

主要发现

  • 匹配后每组1446人,中位年龄38岁,85%为男性,基线平均体重73 kg。
  • 转换为TAF者较继续TDF者144周体重平均增加+0.5 kg,超重或肥胖发生率无差异。
  • 转换为TAF者总胆固醇升高+7.9 mg/dL、甘油三酯升高+11.2 mg/dL,总胆固醇-HDL比值无差异。
  • 随访144周后,糖尿病、高血压及降脂药物使用发生率未见增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tenofovir alafenamide (TAF) has replaced tenofovir disoproxil fumarate (TDF) in many clinical settings. However, concerns remain about potential metabolic complications of TAF. We aimed to evaluate changes in weight, laboratory markers, and metabolic-related clinical events after replacing TDF with TAF. METHODS: Multicenter prospective cohort study in the Spanish CoRIS cohort. We included virologically suppressed adults with human immunodeficiency virus (HIV) receiving TDF for more than 12 months who either switched to TAF or maintained TDF, with no changes in the core agent. Participants were matched by propensity score. We fitted generalized equation models to assess changes in weight, blood lipids, and hepatic steatosis index, and to compare the incidence of diabetes, hypertension, and lipid-lowering drug use after 144 weeks. RESULTS: In total, 1446 participants were matched in each group. Median age was 38 years, 85% were male, mean weight at baseline was 73 kg. Participants who switched to TAF had a mean weight increase of +0.5 kg at 144 weeks over those who maintained TDF, with no difference in the occurrence of overweight or obesity. Individuals who switched to TAF had a significant increase in total cholesterol (+7.9 mg/dL) and triglycerides (+11.2 mg/dL), with no differences in the total cholesterol-high-density lipoprotein (HDL) ratio. However, no increased incidence of diabetes, hypertension, or lipid-lowering drug use was observed after the follow-up period. CONCLUSIONS: Switching from TDF to TAF is associated with modest weight gain and increases in total cholesterol and triglycerides, without an impact on the incidence of obesity or metabolic-related clinical events, in this Spanish cohort with a majority White male population.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Martínez-Sanz J, Serrano-Villar S, Muriel A, et al. Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study. Clin Infect Dis. 2023. PMID: 35903910. doi:10.1093/cid/ciac621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。